Novartis AG vs Natco Pharma Limited

Judicial Analysis Court Copy Headnote Facts Arguments Court observation

DELHI HIGH COURT
C.HARI SHANKAR
Novartis AG – Appellant
Versus
Natco Pharma Limited – Respondent

Table of Content
1. plaintiffs' entitlement to interlocutory injunction. (Para 1 , 4 , 5 , 6)
2. arguments on validity of patent in 161. (Para 2 , 7 , 9 , 10)
3. court observations regarding pharmaceutical patent challenges. (Para 11 , 12 , 33 , 40)
4. legal standards on patentability and infringement. (Para 14 , 35)
5. order granting injunction against the defendant. (Para 41)

JUDGMENT

I.A.6980/2021 (under Order XXXIX Rules 1 & 2 of CPC)

1. This order decides IA 6980/2021, whereby the plaintiffs have sought an interlocutory injunction against the perceived infringement, by the defendant, Natco Pharma Ltd, of the plaintiffs' suit patent IN 233161 (in short, `IN 161').

2. Arguments were advanced on behalf of the plaintiffs by Mr. Hemant Singh, and on behalf of the defendant by Mr. J. Sai Deepak. Copious written submissions have also been filed by both sides.

3. The plaintiffs would collectively be referred to, hereinafter, for ease of reference, as "Novartis".

Facts

4. The suit patent was originally granted to M/s Smith Kline Beecham Corporation (later renamed "GlaxoSmithKline LLC") on 27th March, 2009. Novartis claims that the suit patent was first assigned by GlaxoSmithKline LLC

Click Here to Read the rest of this document

DELHI HIGH COURTC.HARI SHANKARNovartis AG – AppellantVersusNatco Pharma Limited – Respondent

DELHI HIGH COURT
C.HARI SHANKAR
Novartis AG – Appellant
Versus
Natco Pharma Limited – Respondent